BioSpace News Archive

The Get Iron Informed survey sheds light on knowledge of Iron Deficiency Anemia (IDA) - a condition that impacts one in five women of childbearing age

AbFero Ltd., a subsidiary of AbFero Pharmaceuticals, Inc. , a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, today announced the award of a grant from Cure Parkinson’s

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an agreement with Newport Plastic and Reconstructive Surgery Associates for an investigator-initiated study

Retrospective case series published in the Journal of Shoulder and Elbow Surgery examines 63 shoulders in patients up to 85 years of age; outcomes show significant improvements in motion and patient-reported measures

NANO-X IMAGING LTD (NASDAQ: NNOX) (“ Nanox ” or the “ Company ”), an innovative medical imaging technology company, announces that it will release its fourth quarter and full year 2020 financial and operating results for the period ended December 31, 2020 on Tuesday, March 2, 2021 prior to the start of trading.

AI-based Software Providing Physicians with Quantitative Evaluation of CT Scans (QCT) for the Non-invasive Determination of Patient Eligibility for the Spiration Valve System Procedure to Treat Severe Emphysema

Proceeds will advance the lead asset ELI-002, a mKRAS therapeutic cancer vaccine, into a Phase 1/2 clinical trial. Platform technology innovation will continue development of next generation immunotherapies including AMP-adjuvant enabled vaccines, cell therapy programs, and more.

LION Eye Group announces it has entered into a collaborative agreement with OCLI-Spectrum Vision Partners for integrated eye care.

Tauriga Sciences, Inc., a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums as well as an ongoing Pharmaceutical Development initiative, announced a planned increase in the Company’s marketing budget, to support the accelerated growth in its highest margin E-Commerce business segment.

Under the terms of the agreement, signed on February 16, 2021, Glow has exclusive rights to market, sell and distribute ArtemiC™ in Canada, U.S., Mexico and all Carribean countries as a food supplement.